CC
DRNA

Centiva Capital’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Centiva Capital’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,036
Closed -$375K – 1774
2021
Q2 		$375K Buy
+10,036
New +$308K 0.01% 950
2020
Q3 		– Sell
-13,596
Closed -$345K – 937
2020
Q2 		$345K Buy
+13,596
New +$293K 0.02% 373

Other funds holding DRNA

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Centiva Capital's DRNA Position: Q3 2021 in Review

Centiva Capital sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 10,036 shares — an estimated $375K sold.

Centiva Capital first reported a position in DRNA in Q2 2020 and held it in 2 quarters. The position peaked at $375K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

  • Centiva Capital reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Centiva Capital sold 10,036 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $375K.
  • Centiva Capital first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2020 and held it in 2 quarters.
  • Centiva Capital's Dicerna Pharmaceuticals, Inc. position peaked at $375K in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Centiva Capital's 13F filing for Q3 2021, filed 15 Nov 2021.